Distributions in Markov Chain Monte Carlo
As described in Materials and Methods in the Main Text, the methylation data for the 67 BE clock CpG set from a single patient i, for i = 1, . . . , N , observed at time t i , is of the form y i = {y BEi,j , j = 1, . . . , 67}.
(
Here we define the following variables: the onset of BE at time T BE = s i , the slope (b SQj ) and intercept (α SQj ) of the SQ population regression lines (obtained from individuals with matched samples in data set D2 and thus fixed), the patient-specific, CpG-specific BE drift rates b i,j , and the standard deviation σ BEi around data measurement values. For each data set of size N patients, we observe 67 independent measurements for each independent individual. In the Bayesian BE clock model framework, the likelihood contribution from a single patient observed at time t i is given by f N (y BEi,j ; µ BEi,j = α SQj + b SQj s i + b i,j (t i − s i ), σ BEi ), (2) where f N is the normal density function. For those Bayesian model parameters to be inferred, we assume prior distributions p s (s i ), p b (b i,j ), p σ (σ BEi ) to be used in Markov Chain Monte Carlo (MCMC). First, we assume uniform priors p s (s i ) for the BE onset times s i (due to the fact that the distribution of BE onset times in the general population is essentially unknown),
where individual i was age t i at time of biopsy and thus developed BE at some previous age s i . Second, we assume normal prior distributions p b (b i,j ) for the drift rates b i,j , j = 1, . . . , 67,
where the empirical mean µ b and standard deviation σ b were derived from the longitudinal data sets D1 and DV. For discovery set D1 used during CpG marker selection, we computed from regression slopes that the drift rates for the 67 CpG set have mean rate µ b = 0.0650 with standard deviation σ b = 0.0296. For validation set DV that was not used during selection, the drift rates computed for the same 67 CpG set have mean rate µ b = 0.0444 with standard deviation σ b = 0.0439. As expected, we see selection bias manifested by a slightly increased mean slope and decreased variance in data set D1 because that data was used for marker selection of significant CpG drift across individuals via regression (see Fig 5 in 
Thus we simulate posterior distribution samples for model parameters of this Bayesian BE clock model using MCMC. With the expressions above, the full conditionals for our Gibbs sampler can be routinely worked out [1] .
Robustness of Estimates using Imputed SQ Drift
To analyze the robustness of imputing SQ trends for BE onset age estimation, we consider a slightly modified model to that which is currently given in Eqns. (1) (2) (3) (4) (5) in the Main Text. Rather than considering the random variable of interest to be the M-value measurement Y BEi,j (t i ) for each BE patient, the reformulated model considers the difference, ∆ i,j , in M-values between BE and SQ samples in patient i, CpG j, given by the following,
Thus, the observation from a single D2 patient i, for i = 1, . . . , N , observed at time t i , in the unmasked version is of the form
In contrast, the method to infer onset ages we use in the Main Text does not explicitly use the matched SQ sample in an individual's MCMC. Specifically, we currently 'mask' the patientspecific SQ M-values by using fixed intercept α SQj and slope b SQj for each CpG j attained from linear regression across all D2 patients. We then apply this approach to other data sets such as D3 who do not have SQ-matched samples. Analogously written in the difference (∆) model formulation, this masked version would use observations of the form
Thus, the analog to Eq. (5) in the Main Text would be the following equation for the posterior distribution of parameter vector Ψ i given the observation y i for patient i,
where the normal prior p b is adjusted to estimate parameter b i,j − b SQj with appropriate mean and standard deviation, and gamma prior p σ now applies to standard deviation of the sum of two normal random variables,
We ran the Bayesian BE clock model for all patients in D2 using the unmasked (Eq. (9)) and masked (Eq. (10)) versions of the ∆ model above to determine if the lack of paired SQ matched data leads to any information loss in individual BE onset age estimation among the D2 patients. We found that using an imputation of the intercept and drift rates rather than exact matched SQ values is a robust approach to estimating BE onset ages (see S5 Fig for  comparison) . Specifically, the correlation of median estimates between the two methods was .98, and the root-mean-square error between onset ages was 0.08 years. Thus, there is minimal information loss resulting from a lack of matched SQ tissue samples for the D2 patients. This is an advantageous aspect of our approach for BE dwell time estimation, particularly for future validation opportunities that may be limited to strictly BE tissue samples as was the case for data set D3.
Lifetime EAC Risk Derivation
In the Main Text, we compute the risk of developing EAC by age 88 in a cancer-free individual at time of biopsy/diagnosis a, given estimated BE onset time, with the multistage clonal expansion for EAC (MSCE-EAC) model (S1 Fig) that was previously calibrated to Surveillance, Epidemiology, and End Results (SEER) incidence data [2] [3] [4] . This risk is defined as the probability of developing EAC at random time T EAC by age 88 conditional on the onset age of BE, T BE . For each BE patient who has not been diagnosed with EAC at age at biopsy a, with BE onset time estimated to be age s from his/her methylation profile, we computed the following risk
where S M SCE is the EAC survival probability for the MSCE-EAC model given BE onset (thus simply an MSCE model). This function has been derived previously (see S1 Text of [4] ) but for completeness we will provide a derivation here as well. We first introduce the notation for the following random variables of the multi-type branching process BE(t) = Bernoulli random variable for BE conversion by time t X(t) = number of BE stem cells in a tissue at time t P * (t) = number of pre-initiated cells at time t P (t) = number of premalignant (initiated) cells at time t
M (t) = number of malignant (preclinical) cells (prior to detection) at time t C(t) = number of cancer cells (after detection) at time t D(t) = Bernoulli random variable for clinical detection by time t
Let us consider the probability generating function (pgf) Ψ for the entire process starting at τ = 0, ie. when an individual is born
where, explicitly, i, n = {0, 1} and BE(t), D(t) are the following indicator functions corresponding to BE conversion and EAC clinical detection, respectively BE(t) = 0 if BE has not developed by time t 1 if BE conversion has taken place by time t D(t) = 0 if no cancer detected clinically by time t 1 if a malignant cell is detected by time t. ie C(τ ) > 0 for some τ ≤ t
The Chapman-Kolmogorov equations governing the transition probabilities for this multistage process include contributions from the initial Armitage-Doll type transition to BE, the two Poisson transitions to initiation, and the two birth-death-migration processes, all of which have been derived previously [5] [6] [7] . We begin with a method for solving for these generating functions using the Kolmogorov backward equations. Backward Kolmogorov equations and the MSCE hazard, S M SCE Beginning with an active BE segment (BE), a single pre-initiated (P * ), premalignant (P ), or malignant (M ) cell at time τ only, we define the following generating functions Φ BE ,Φ P * , Φ P , or Φ M , respectively,
Φ P * (y 1 ,y 2 ,y 3 ,z;τ,t)=E[y
Φ BE (y BE ,y 1 ,y 2 ,y 3 ,z;τ,t)=E[y
The generating functions satisfy the following Kolmogorov backward equations
∂Φ P * (y 1 , y 2 , y 3 , z; τ, t) ∂τ
∂Φ BE (y BE , y 1 , y 2 , y 3 , z; τ, t) ∂τ
To connect the cellular level description to the population level, we first solve for the overall survival function (for EAC cancer detection), starting at time 0, which in our notation is
where P EAC (t) is the probability of a cancer detection at time t,
We will here denote
, and Ψ(1, 1, 1, 1, 0; τ, t) ≡ Ψ(τ, t). A dot designates a first derivative with respect to t. The hazard function, i.e., the rate at which cancer is detected in individuals who have not been diagnosed before, is given by
For fixed t, this boundary value system of coupled PDEs can be converted into an initial value problem (IVP) with the change of variables u = t−τ , where u is the "running" time. This redefinition and equations hereafter follow the method used by Crump et al. [8] . Define the following variables for the new IVP:
with corresponding initial conditions Y 1 (0, t) = Y 3 (0, t) = Y 5 (0, t) = Y 7 (0, t) = Y 9 (0, t) = 1, Y 4 (0, t) = Y 6 (0, t) = Y 8 (0, t) = Y 10 (0, t) = 0, and Y 2 (0, t) = −ρ. Then the equations to solve for our IVP are the following
dY 3 (u, t) du = β P + µ 2 Y 1 (u, t)Y 3 (u, t) − (α P + β P + µ 2 )Y 3 (u, t) + α P Y 
dY 9 (u, t) du = ν(u)(Y 7 (u, t) − Y 9 (u, t))
dY 10 (u, t) du = ν(u)(Y 10 (u, t) − Y 8 (u, t)).
These 10 coupled ODEs can be solved numerically to obtain the desired survival function conditional on time of BE onset from Eq. (12), S M SCE (t) = Y 7 (t, t).
